- Home
- PK vs CPRX Comparison
PK vs CPRX Comparison
Compare PK & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- CPRX
- Stock Information
- Founded
- PK 1946
- CPRX 2002
- Country
- PK United States
- CPRX United States
- Employees
- PK 91
- CPRX N/A
- Industry
- PK Real Estate Investment Trusts
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- PK Real Estate
- CPRX Health Care
- Exchange
- PK Nasdaq
- CPRX Nasdaq
- Market Cap
- PK 2.2B
- CPRX 2.6B
- IPO Year
- PK N/A
- CPRX 2006
- Fundamental
- Price
- PK $11.11
- CPRX $21.01
- Analyst Decision
- PK Hold
- CPRX Strong Buy
- Analyst Count
- PK 11
- CPRX 5
- Target Price
- PK $12.27
- CPRX $33.20
- AVG Volume (30 Days)
- PK 3.1M
- CPRX 1.4M
- Earning Date
- PK 10-30-2025
- CPRX 11-05-2025
- Dividend Yield
- PK 12.67%
- CPRX N/A
- EPS Growth
- PK N/A
- CPRX 183.96
- EPS
- PK 0.28
- CPRX 1.65
- Revenue
- PK $2,589,000,000.00
- CPRX $558,499,000.00
- Revenue This Year
- PK $0.61
- CPRX $16.59
- Revenue Next Year
- PK $2.13
- CPRX $8.80
- P/E Ratio
- PK $39.66
- CPRX $12.72
- Revenue Growth
- PK N/A
- CPRX 28.55
- 52 Week Low
- PK $8.27
- CPRX $19.05
- 52 Week High
- PK $16.23
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- PK 50.56
- CPRX 55.01
- Support Level
- PK $10.43
- CPRX $20.66
- Resistance Level
- PK $11.22
- CPRX $21.55
- Average True Range (ATR)
- PK 0.32
- CPRX 0.61
- MACD
- PK 0.05
- CPRX 0.04
- Stochastic Oscillator
- PK 75.65
- CPRX 67.88
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 22,395 rooms across 36 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).